Skip to main content
placeholder image

Prognostic, predictive, and surrogate value of HER2 extracellular domain (ECD) for progression-free survival (PFS) in advanced breast cancer treated with lapatinib (lap): A meta-analysis.

Journal Article


Abstract


UOW Authors


  •   De Souza, Paul (external author)

Publication Date


  • 2014

Citation


  • Lee, C., Davies, L., Marschner, I., Gebski, V., Lord, S., Di Leo, A., . . . De Souza, P. (2014). Prognostic, predictive, and surrogate value of HER2 extracellular domain (ECD) for progression-free survival (PFS) in advanced breast cancer treated with lapatinib (lap): A meta-analysis.. Journal of Clinical Oncology, 32(15_suppl), 630. doi:10.1200/jco.2014.32.15_suppl.630

Web Of Science Accession Number


Start Page


  • 630

End Page


  • 630

Volume


  • 32

Issue


  • 15_suppl

Place Of Publication


Abstract


UOW Authors


  •   De Souza, Paul (external author)

Publication Date


  • 2014

Citation


  • Lee, C., Davies, L., Marschner, I., Gebski, V., Lord, S., Di Leo, A., . . . De Souza, P. (2014). Prognostic, predictive, and surrogate value of HER2 extracellular domain (ECD) for progression-free survival (PFS) in advanced breast cancer treated with lapatinib (lap): A meta-analysis.. Journal of Clinical Oncology, 32(15_suppl), 630. doi:10.1200/jco.2014.32.15_suppl.630

Web Of Science Accession Number


Start Page


  • 630

End Page


  • 630

Volume


  • 32

Issue


  • 15_suppl

Place Of Publication